Frederick, MD (PRWEB) June 06, 2015
A2LA is proud to announce the accreditation of its first clinical testing laboratory as part of its CMS-recognized Clinical Accreditation Program. ASPiRA Labs, located in Georgetown, TX, was awarded accreditation by A2LA on April 30, 2015.
With this recognition, ASPiRA becomes the first U.S.-based laboratory to successfully complete A2LA’s CLIA Accreditation Program. The accreditation recognizes ASPiRA’s commitment to providing the highest quality laboratory services and testing results to their patients.
“I am delighted to welcome ASPiRA Labs to A2LA's family of accredited laboratories. We appreciate their confidence in our CLIA assessment process and know that their A2LA accreditation will enhance their ability to provide superior service to their clients,” states Roxanne Robinson, A2LA Vice President/COO.
Valerie Palmieri, President and CEO of Vermillion, Inc., the parent company of ASPiRA Labs, commented, “CLIA certification is a big step forward for ASPiRA Labs in our goal to become a leading laboratory in women’s health diagnostics and bioanalytics. We’re proud to set the bar high and be accredited by a forward-looking, innovative and professional accreditation body like A2LA.”
A2LA is an internationally recognized Accreditation Body with over 35 years of experience accrediting laboratories in a multitude of fields and offering a variety of public and private training across all disciplines. A2LA is the largest multi-discipline accreditation body in the United States and has been operating as a non-profit, public service, membership society since 1978. A2LA offers accreditation to ISO 15189:2012 and to the CLIA requirements for clinical testing laboratories and also a dual accreditation to both ISO 15189:2012 and CLIA, resulting in a single accreditation from one assessment by one team of assessors at a single price. A2LA accreditation offers clinical laboratories the ability to mitigate errors and risk while increasing international business opportunities and gaining a clear competitive advantage.
About ASPiRA Labs:
ASPiRA Labs is an innovative diagnostic services laboratory founded by Vermillion, Inc., a leader in women's health diagnostics. The laboratory's goal is to provide high quality, innovative testing and bio-analytics for women to help address unmet women's health needs. ASPiRA Labs' specialized services are grounded in evidence-based medicine, while providing access to novel biomarker diagnostic tools designed to help health care professionals offer the most precise diagnoses and treatment guidance for their patients. ASPiRA Labs currently offers OVA1, a proprietary FDA-cleared blood test to help physicians assess the risk of ovarian cancer prior to surgery and trigger the involvement of a specialist (gynecologic oncologist) for higher risk patients. To learn more about ASPiRA Labs, visit http://www.aspiralab.com.